ArticleClinical and translational medicine2024

TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies.

Lianjun He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.